Cutaneous adverse events of new anti-melanoma therapies: classification and management

Written by Dr Shelley Hwang
Recently, we have published a review article describing “Cutaneous adverse events of new anti-melanoma therapies: classification and management” in Actas Dermo-sifiliograficas. The review article describes comprehensive summary of cutaneous adverse events that emerge with the use of systemic anti-melanoma therapies such as BRAF inhibitors, MEK inhibitors, a combination of BRAF and MEK inhibitors, anti-CTLA4 antibodies and anti-PD1 antibodies, a combination of anti-CTLA4 and anti-PD1 antibody in patients with metastatic melanoma. The review also describes management approach to these wide range of cutaneous toxicities. We hope this review will aid clinicians in diagnosing and treating a wide range of cutaneous toxicities that appear in patients with metastatic melanoma.